Onco-Inmunología Aplicada y Traslacional
O-I Traslacional
![Foto de Onco-Inmunología Aplicada y Traslacional](/img/uploaded/5e1e7ce08027cbcdc3493fed993191d0.jpg)
![Foto de Clínica Universitaria de Navarra](/img/noimage_org.png)
Clínica Universitaria de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (47)
2024
2023
-
Reply to letter to the editor “Bureaucracy or Streamlining the Rules in “Good Clinical Practice (GCP)” - Has Equipoise Occurred?” by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna
Annals of Oncology
-
Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials
Annals of Oncology, Vol. 34, Núm. 1, pp. 70-77
2022
-
Long-Term Outcome of Critically Ill Advanced Cancer Patients Managed in an Intermediate Care Unit
Journal of Clinical Medicine, Vol. 11, Núm. 12, pp. 3472
2021
-
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic
Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26
-
IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy
Clinical Cancer Research, Vol. 27, Núm. 9, pp. 2383-2393
-
Senescent T cells as a resistance mechanism to lung cancer immunotherapy
Clinical Cancer Research, Vol. 27, Núm. 2, pp. 374-376
2020
2019
-
Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Actas Dermo-Sifiliograficas, Vol. 110, Núm. 6, pp. 448-459
-
Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 21, Núm. 5, pp. 556-571
-
Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells
OncoImmunology, Vol. 8, Núm. 7
-
Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis
Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4663-4673
-
Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer
International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001
-
Programmed death–ligand 1 expression on direct Pap-stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens
Cancer Cytopathology, Vol. 127, Núm. 7, pp. 470-480
2018
-
Neoadjuvant immunotherapy in non-small cell lung cancer: The sooner the better?
Translational Lung Cancer Research
2017
-
Interleukin-8 in cancer pathogenesis, treatment and follow-up
Cancer Treatment Reviews, Vol. 60, pp. 24-31
-
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Cancer Treatment Reviews, Vol. 53, pp. 79-97
2016
-
SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)
Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1237-1242
-
Tumor-Produced Interleukin-8 Attracts human myeloid-derived suppressor cells and elicits extrusion of Neutrophil Extracellular Traps (NETs)
Clinical Cancer Research, Vol. 22, Núm. 15, pp. 3924-3936
2015
-
Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer
Cancer Cytopathology, Vol. 123, Núm. 4, pp. 230-236